Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Prognostic implications of ezrin and phosphorylated ezrin expression in non-small cell lung cancer

Authors: Tiefeng Jin, Jingchun Jin, Xiangyu Li, Songnan Zhang, Yun Ho Choi, Yingshi Piao, Xionghu Shen, Zhenhua Lin

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

The cytoskeletal organizer ezrin is a member of the ezrin-radixin-moesin (ERM) family and plays important roles in not only cell motility, cell adhesion, and apoptosis, but also in various cell signaling pathways. Phosphorylation at Thr-567 and Tyr-353 are key regulatory events in the transition of the dormant to active form of ezrin. This study investigated the prognostic implications of ezrin and phosphorylated ezrin (p-ezrin) expression in non-small cell lung carcinoma (NSCLC).

Methods

Ezrin and p-ezrin protein expressions were examined by immunohistochemistry in 150 NSCLC and adjacent non-tumor tissues and 14 normal lung tissues. qRT-PCR was used to determine ezrin mRNA expression levels in fresh tissues. The correlations between overexpression of ezrin and p-ezrin and the clinicopathological features of NSCLC were analyzed. The survival rates were calculated by the Kaplan-Meier method for 108 NSCLC cases.

Results

Ezrin and ezrinThr-567 proteins showed cytosolic and membranous staining patterns; however, ezrinTyr-353 protein only showed cytosolic staining. Ezrin and p-ezrin were significantly upregulated in NSCLC compared with the normal counterparts. Increased ezrin, ezrinThr-567, and ezrinTyr-353 levels were correlated with the late stage and poor differentiation of NSCLC. However, only ezrinThr-567 was correlated with the presence of lymph node metastasis. In regard to survival, only ezrinThr-567 was related with the overall survival time of patients with NSCLC, and both ezrin and ezrinThr-567 were associated with shortened survival time for patients with early stage NSCLC.

Conclusions

Ezrin and p-ezrin, especially ezrinThr-567, may prove to be useful as a novel prognostic biomarker of NSCLC.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 2007, 57: 43-66. 10.3322/canjclin.57.1.43.CrossRefPubMed
2.
Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E: Cancer treatment and survivorship statistics 2012. CA Cancer J Clin. 2012, 62: 220-241. 10.3322/caac.21149.CrossRefPubMed
3.
Chen X, Liu Y, Røe OD, Qian Y, Guo R, Zhu L, Yin Y, Shu Y: Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review. PLoS One. 2013, 8 (3): e59314-10.1371/journal.pone.0059314.CrossRefPubMedPubMedCentral
4.
Gaughan EM, Costa DB: Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Ther Adv Med Oncol. 2011, 3 (3): 113-125. 10.1177/1758834010397569.CrossRefPubMedPubMedCentral
5.
Lee HW, Kim EH, Oh MH: Clinicopathologic implication of ezrin expression in non-small cell lung cancer. Korean J Pathol. 2012, 46 (5): 470-477. 10.4132/KoreanJPathol.2012.46.5.470.CrossRefPubMedPubMedCentral
6.
Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM, Helman LJ: The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004, 10 (2): 182-186. 10.1038/nm982.CrossRefPubMed
7.
Zhu J, Feng Y, Ke Z, Yang Z, Zhou J, Huang X, Wang L: Down-regulation of miR-183 promotes migration and invasion of osteosarcoma by targeting ezrin. Am J Pathol. 2012, 180 (6): 2440-2451. 10.1016/j.ajpath.2012.02.023.CrossRefPubMed
8.
Bretscher A, Edwards K, Fehon RG: ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol. 2002, 3: 586-599. 10.1038/nrm882.CrossRefPubMed
9.
Turunen O, Wahlström T, Vaheri A: Ezrin has a COOH-terminal actin-binding site that is conserved in the ezrin protein family. J Cell Biol. 1994, 126: 1445-1453. 10.1083/jcb.126.6.1445.CrossRefPubMed
10.
Liu Y, Belkina NV, Park C, Nambiar R, Loughhead SM, Patino-Lopez G, Ben-Aissa K, Hao JJ, Kruhlak MJ, Qi H, von Andrian UH, Kehrl JH, Tyska MJ, Shaw S: Constitutively active ezrin increases membrane tension, slows migration, and impedes endothelial transmigration of lymphocytes in vivo in mice. Blood. 2012, 119 (2): 445-453. 10.1182/blood-2011-07-368860.CrossRefPubMedPubMedCentral
11.
Fievet BT, Gautreau A, Roy C, Del Maestro L, Mangeat P, Louvard D, Arpin M: Phosphoinositide binding and phosphorylation act sequentially in the activation mechanism of ezrin. J Cell Biol. 2004, 164: 653-659. 10.1083/jcb.200307032.CrossRefPubMedPubMedCentral
12.
Elzagheid A, Korkeila E, Bendardaf R, Buhmeida A, Heikkilä S, Vaheri A, Syrjänen K, Pyrhönen S, Carpén O: Intense cytoplasmic ezrin immunoreactivity predicts poor survival in colorectal cancer. Hum Pathol. 2008, 39 (12): 1737-1743. 10.1016/j.humpath.2008.04.020.CrossRefPubMed
13.
Lin L, Piao J, Gao W, Piao Y, Jin G, Ma Y, Li J, Lin Z: DEK over expression as an independent biomarker for prognosis in colorectal cancers. BMC Cancer. 2013, 13: 366-10.1186/1471-2407-13-366.CrossRefPubMedPubMedCentral
14.
Gautreau A, Poullet P, Louvard D, Arpin M: Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A. 1999, 96 (13): 7300-7305. 10.1073/pnas.96.13.7300.CrossRefPubMedPubMedCentral
15.
Martin GS: Cell signaling and cancer. Cancer Cell. 2003, 4 (3): 167-174. 10.1016/S1535-6108(03)00216-2.CrossRefPubMed
16.
McClatchey AI: Merlin and ERM proteins: unappreciated roles in cancer development?. Nat Rev Cancer. 2003, 3 (11): 877-883. 10.1038/nrc1213.CrossRefPubMed
17.
Xie JJ, Xu LY, Xie YM, Zhang HH, Cai WJ, Zhou F, Shen ZY, Li EM: Roles of ezrin in the growth and invasiveness of esophageal squamous carcinoma cells. Int J Cancer. 2009, 124 (11): 2549-2558. 10.1002/ijc.24216.CrossRefPubMed
18.
Moilanen J, Lassus H, Leminen A, Vaheri A, Bützow R, Carpén O: Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients. Gynecol Oncol. 2003, 90 (2): 273-281. 10.1016/S0090-8258(03)00262-2.CrossRefPubMed
19.
Karmakar S, Das C: Modulation of ezrin and E-cadherin expression by IL-1beta and TGF-beta1 in human trophoblasts. J Reprod Immunol. 2004, 64 (1–2): 9-29.CrossRefPubMed
20.
Zhang XQ, Chen GP, Wu T, Yan JP, Zhou JY: Expression and clinical significance of ezrin in non-small cell lung cancer. Clin Lung Cancer. 2012, 13 (3): 196-204. 10.1016/j.cllc.2011.04.002.CrossRefPubMed
21.
Grune T, Reinheckel T, North JA, Li R, Bescos PB, Shringarpure R, Davies KJ: Ezrin turnover and cell shape changes catalyzed by proteasome in oxidatively stressed cells. FASEB J. 2002, 16 (12): 1602-1610. 10.1096/fj.02-0015com.CrossRefPubMed
22.
Zhu L, Zhou R, Mettler S, Wu T, Abbas A, Delaney J, Forte JG: High turnover of ezrin Thr567 phosphorylation: conformation, activity, and cellular function. Am J Physiol Cell Physiol. 2007, 293 (3): 874-884. 10.1152/ajpcell.00111.2007.CrossRef
23.
Chen Y, Wang D, Guo Z, Zhao J, Wu B, Deng H, Zhou T, Xiang H, Gao F, Yu X, Liao J, Ward T, Xia P, Emenari C, Ding X, Thompson W, Ma K, Zhu J, Aikhionbare F, Dou K, Cheng SY, Yao X: Rho kinase phosphorylation promotes ezrin-mediated metastasis in hepatocellular carcinoma. Cancer Res. 2011, 71: 1721-1729. 10.1158/0008-5472.CAN-09-4683.CrossRefPubMedPubMedCentral
24.
Krishnan K, Bruce B, Hewitt S, Thomas D, Khanna C, Helman LJ: Ezrin mediates growth and survival in Ewing’s sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway. Clin Exp Metastasis. 2006, 23: 227-236. 10.1007/s10585-006-9033-y.CrossRefPubMed
25.
Cui Y, Li T, Zhang D, Han J: Expression of ezrin and phosphorylated ezrin (pEzrin) in pancreatic ductal adenocarcinoma. Cancer Invest. 2010, 28 (3): 242-247. 10.3109/07357900903124498.CrossRefPubMed
26.
Lan M, Kojima T, Murata M, Osanai M, Takano K, Chiba H, Sawada N: Phosphorylation of ezrin enhances microvillus length via a p38 MAP-kinase pathway in an immortalized mouse hepatic cell line. Exp Cell Res. 2006, 312 (2): 111-120. 10.1016/j.yexcr.2005.09.018.CrossRefPubMed
27.
Oda Y, Aishima S, Morimatsu K, Hayashi A, Shindo K, Fujino M, Mizuuchi Y, Hattori M, Tanaka M, Oda Y: Differential ezrin and phosphorylated ezrin expression profiles between pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and invasive ductal carcinoma of the pancreas. Hum Pathol. 2013, 44 (8): 1487-1498. 10.1016/j.humpath.2012.12.001.CrossRefPubMed
28.
Di Cristofano C, Leopizzi M, Miraglia A, Sardella B, Moretti V, Ferrara A, Petrozza V, Della Rocca C: Phosphorylated ezrin is located in the nucleus of the osteosarcoma cell. Mod Pathol. 2010, 23 (7): 1012-1020. 10.1038/modpathol.2010.77.CrossRefPubMed
29.
Orr Gandy KA, Adada M, Canals D, Carroll B, Roddy P, Hannun YA, Obeid LM: Epidermal growth factor-induced cellular invasion requires sphingosine-1-phosphate/sphingosine-1-phosphate 2 receptor-mediated ezrin activation. FASEB J. 2013, 27 (8): 3155-3166. 10.1096/fj.13-228460.CrossRefPubMedPubMedCentral
30.
Antelmi E, Cardone RA, Greco MR, Rubino R, Di Sole F, Martino NA, Casavola V, Carcangiu M, Moro L, Reshkin SJ: ß1 integrin binding phosphorylates ezrin at t567 to activate a lipid raft signalsome driving invadopodia activity and invasion. PLoS One. 2013, 8 (9): e75113-10.1371/journal.pone.0075113.CrossRefPubMedPubMedCentral
Metadata
Title
Prognostic implications of ezrin and phosphorylated ezrin expression in non-small cell lung cancer
Authors
Tiefeng Jin
Jingchun Jin
Xiangyu Li
Songnan Zhang
Yun Ho Choi
Yingshi Piao
Xionghu Shen
Zhenhua Lin
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-191

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Intratumoral heterogeneity impacts the response to anti-neu antibody therapy

Research article

Expression of A disintegrin and metalloprotease 8 is associated with cell growth and poor survival in colorectal cancer

Research article

Endothelial cell-derived interleukin-6 regulates tumor growth

Research article

A simple way to measure the burden of interval cancers in breast cancer screening

Research article

Differential knockdown of TGF-β ligands in a three-dimensional co-culture tumor- stromal interaction model of lung cancer

Research article

Chromosomal imbalances in human bladder urothelial carcinoma: similarities and differences between biopsy samples and cancer stem-like cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits